Tag: Robert Neill

  • Robert Neill – 2022 Speech on Prison Capacity

    Robert Neill – 2022 Speech on Prison Capacity

    The speech made by Sir Robert Neill, the Chair of the Justice Committee, in the House of Commons on 30 November 2022.

    The Minister is right, of course, to take this urgent action, and to say that this is not the first time it has had to be done. Does he recognise that two factors are at play here? One is the underlying upward trend in prisoner numbers over the past couple of decades. Those numbers have risen exponentially, and perhaps there is a case for us to look again at whether it is appropriate to be holding non-violent offenders in custody, as opposed to the dangerous people who we do need to lock up. Secondly, the Minister refers to the levels of investment in maintenance, but as he will know, the Justice Committee has more than once pointed out that even with increased spending on maintenance, there is still a significant backlog and shortfall in the maintenance budget. Many prison cells are therefore out of commission and not usable, when they ought to be brought back into use. What is being done to accelerate the maintenance programme to get more cells back into use?

    Damian Hinds

    I thank the Chair of the Select Committee for those important questions and points. He is right that the prison population has been growing of late, although it is not at its highest level ever. Part of that is because of tougher sentences for the worst offences, which I think is right and what the public expect and want. For other types of crime, it is important that we utilise alternatives to custodial sentences—for instance, drug desistance and advanced tagging, which is much improved—which can, on occasion, be better for getting certain individuals back on the straight and narrow.

    My hon. Friend also rightly asked about maintenance, and accelerated maintenance. In fact, that is precisely what we have done. Two and a half times as many cells are currently undergoing capital works than would ordinarily be the case, precisely because we have brought forward some capital work to improve the estate. We are indeed planning for the future.

  • Robert Neill – 2015 Parliamentary Question to the Department of Health

    Robert Neill – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Robert Neill on 2015-10-19.

    To ask the Secretary of State for Health, for what reasons his recent assessment of NHS England’s performance against the Mandate in 2014-15 did not address NHS England’s performance in meeting the requirement contained in the Mandate to ensure that people have access to the right treatment when they need it.

    George Freeman

    The Secretary of State’s annual assessment of NHS England’s performance in 2014-15 sets out specifically his evaluation of NHS England’s performance in meeting the access standards set out in the NHS Constitution.

    In addition, the Secretary of State’s annual assessment sets out that he agrees with NHS England’s own assessment, as set out in its annual report for 2014-15, that it has made good progress against delivering its objectives in the mandate, which includes ensuring that people have the right treatment when they need it.

  • Robert Neill – 2015 Parliamentary Question to the Department of Health

    Robert Neill – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Robert Neill on 2015-10-19.

    To ask the Secretary of State for Health, what information his Department holds on when the Health and Social Care Information Centre expects its innovation scorecard to attain the status of non-experimental statistics; what steps that centre is taking to improve the data quality of that scorecard; and if he will make a statement.

    George Freeman

    The Health and Social Care Information Centre is working towards the removal of the experimental status of the innovation scorecard during the first half of 2016. The data already complies with the UK Statistics Authority’s Code of Practice for Official Statistics.

  • Robert Neill – 2015 Parliamentary Question to the Department of Health

    Robert Neill – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Robert Neill on 2015-10-19.

    To ask the Secretary of State for Health, in which months the implementation of commitments to increase access to treatments contained in the Pharmaceutical Price Regulation Scheme has been discussed in NHS England accountability meetings.

    George Freeman

    Improving patients’ access to innovative, National Institute for Health and Care Excellence approved treatments is part of an objective set out in the Government’s mandate to NHS England. Performance against the mandate is discussed in NHS England accountability meetings chaired by the Secretary of State. The minutes of the meetings are published on the Government’s website at:

    https://www.gov.uk/government/publications/nhs-commissioning-board-accountability-meeting-minutes

  • Robert Neill – 2015 Parliamentary Question to the Department of Health

    Robert Neill – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Robert Neill on 2015-10-19.

    To ask the Secretary of State for Health, which organisation provides the secretariat for the NICE Implementation Collaborative; what the Collaborative’s current priorities and work programmes are; what funding the Collaborative has received from the public purse since it was established; and if he will make a statement.

    George Freeman

    The National Institute for Health and Care Excellence (NICE) has advised that it has provided the secretariat function for the NICE Implementation Collaborative (NIC) since January 2014 as part of a wider memorandum of understanding with NHS England. This year, the NIC agreed to undertake work in the following four areas, each of which was agreed because of their potential to generate learning about how to support uptake of NICE guidance:

    – Improving patient outcomes for patients with non ST Elevation acute Coronary Syndromes;

    – Improving Tuberculosis screening and data collection across health and social care;

    – Identifying appropriate treatment pathways for people with moderate alcohol consumption across health and social care; and

    – Increasing the knowledge base about the factors that increase use of technologies building on previous National Institute for Health Research (NIHR) research.

    NHS England has responsibility for funding any project costs and projects liaise with NHS England to access these funds.

    NHS England has advised that it provided £4,000 in 2014-15 and up to £10,000 in 2015-16.

  • Robert Neill – 2015 Parliamentary Question to the Department of Health

    Robert Neill – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Robert Neill on 2015-10-09.

    To ask the Secretary of State for Health, if he will make it his policy to ensure that the boards of all relevant NHS organisations are responsible for ensuring adherence to the mandatory funding direction for NICE appraisals.

    George Freeman

    NHS England is specified in the 2014 Pharmaceutical Pricing Regulation Scheme agreement as the body responsible for ensuring there are no local barriers to ensuring access to technologies recommended in National Institute for Health and Care Excellence (NICE) technology appraisal and highly specialised technology guidance.

    NHS England has advised that there are a range of initiatives which assist NHS England in this obligation:

    – NICE technology appraisalrecommendations are required to be incorporated automatically into relevant local medicines formularies;

    – providers are required to publish local medicines formularies;

    – the NICE Implementation Collaborative (NIC) examines barriers to the prompt implementation of NICE guidance;

    – an innovation scorecard is published quarterly by the Health and Social Care Information Centre and tracks uptake of many NICE-approved medicines by the NHS;

    – a joint NHS England and Association of the British Pharmaceutical Industry work programme on medicines optimisation is ongoing, which seeks to improve outcomes and value from all medicines;

    – NHS England works closely with Academic Health Science Networks to accelerate the adoption and diffusion of innovation.

    The Department’s analysis of medicines spend for the first year of the PPRS shows that branded medicines spend grew by 8.2%, with new medicines on the Innovation Scorecard seeing growth of 18.4%. Further details have been published on the Government’s website at:

    https://www.gov.uk/government/publications/analysis-of-growth-in-branded-medicines-2013-to-2014

    Commissioners are legally required to fund drugs and treatments recommended in NICE technology appraisal and highly specialised technology guidance within three months of NICE’s guidance being published. There is provision for this funding period to be extended where there are particular barriers to implementation within three months.

  • Robert Neill – 2015 Parliamentary Question to the Department of Health

    Robert Neill – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Robert Neill on 2015-10-09.

    To ask the Secretary of State for Health, what assessment he has made of the compatibility of recent requests by NHS England to delay implementation of NICE guidance with his Department’s commitment to the three month funding requirement in the latest iteration of the Pharmaceutical Price Regulation Scheme; what steps he is taking to ensure that all positive NICE recommendations are funded within three months; and if he will make a statement.

    George Freeman

    NHS England is specified in the 2014 Pharmaceutical Pricing Regulation Scheme agreement as the body responsible for ensuring there are no local barriers to ensuring access to technologies recommended in National Institute for Health and Care Excellence (NICE) technology appraisal and highly specialised technology guidance.

    NHS England has advised that there are a range of initiatives which assist NHS England in this obligation:

    – NICE technology appraisalrecommendations are required to be incorporated automatically into relevant local medicines formularies;

    – providers are required to publish local medicines formularies;

    – the NICE Implementation Collaborative (NIC) examines barriers to the prompt implementation of NICE guidance;

    – an innovation scorecard is published quarterly by the Health and Social Care Information Centre and tracks uptake of many NICE-approved medicines by the NHS;

    – a joint NHS England and Association of the British Pharmaceutical Industry work programme on medicines optimisation is ongoing, which seeks to improve outcomes and value from all medicines;

    – NHS England works closely with Academic Health Science Networks to accelerate the adoption and diffusion of innovation.

    The Department’s analysis of medicines spend for the first year of the PPRS shows that branded medicines spend grew by 8.2%, with new medicines on the Innovation Scorecard seeing growth of 18.4%. Further details have been published on the Government’s website at:

    https://www.gov.uk/government/publications/analysis-of-growth-in-branded-medicines-2013-to-2014

    Commissioners are legally required to fund drugs and treatments recommended in NICE technology appraisal and highly specialised technology guidance within three months of NICE’s guidance being published. There is provision for this funding period to be extended where there are particular barriers to implementation within three months.

  • Robert Neill – 2015 Parliamentary Question to the Department of Health

    Robert Neill – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Robert Neill on 2015-10-09.

    To ask the Secretary of State for Health, with reference to page 20 of the 2014 Pharmaceutical Price Regulation Scheme, which body is responsible for ensuring there should be no local barriers to accessing technologies recommended in NICE guidance; what assessment that body has made of the existence of local barriers since 1 January 2014; and if he will make a statement.

    George Freeman

    NHS England is specified in the 2014 Pharmaceutical Pricing Regulation Scheme agreement as the body responsible for ensuring there are no local barriers to ensuring access to technologies recommended in National Institute for Health and Care Excellence (NICE) technology appraisal and highly specialised technology guidance.

    NHS England has advised that there are a range of initiatives which assist NHS England in this obligation:

    – NICE technology appraisalrecommendations are required to be incorporated automatically into relevant local medicines formularies;

    – providers are required to publish local medicines formularies;

    – the NICE Implementation Collaborative (NIC) examines barriers to the prompt implementation of NICE guidance;

    – an innovation scorecard is published quarterly by the Health and Social Care Information Centre and tracks uptake of many NICE-approved medicines by the NHS;

    – a joint NHS England and Association of the British Pharmaceutical Industry work programme on medicines optimisation is ongoing, which seeks to improve outcomes and value from all medicines;

    – NHS England works closely with Academic Health Science Networks to accelerate the adoption and diffusion of innovation.

    The Department’s analysis of medicines spend for the first year of the PPRS shows that branded medicines spend grew by 8.2%, with new medicines on the Innovation Scorecard seeing growth of 18.4%. Further details have been published on the Government’s website at:

    https://www.gov.uk/government/publications/analysis-of-growth-in-branded-medicines-2013-to-2014

    Commissioners are legally required to fund drugs and treatments recommended in NICE technology appraisal and highly specialised technology guidance within three months of NICE’s guidance being published. There is provision for this funding period to be extended where there are particular barriers to implementation within three months.

  • Robert Neill – 2015 Parliamentary Question to the Department of Health

    Robert Neill – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Robert Neill on 2015-10-09.

    To ask the Secretary of State for Health, with reference to page 20 of the 2014 Pharmaceutical Price Regulation Scheme, what recent assessment he has made of the compliance of NHS bodies with the requirement for the incorporation of NICE technology appraisal recommendations into local NHS formularies.

    George Freeman

    NHS England is specified in the 2014 Pharmaceutical Pricing Regulation Scheme agreement as the body responsible for ensuring there are no local barriers to ensuring access to technologies recommended in National Institute for Health and Care Excellence (NICE) technology appraisal and highly specialised technology guidance.

    NHS England has advised that there are a range of initiatives which assist NHS England in this obligation:

    – NICE technology appraisalrecommendations are required to be incorporated automatically into relevant local medicines formularies;

    – providers are required to publish local medicines formularies;

    – the NICE Implementation Collaborative (NIC) examines barriers to the prompt implementation of NICE guidance;

    – an innovation scorecard is published quarterly by the Health and Social Care Information Centre and tracks uptake of many NICE-approved medicines by the NHS;

    – a joint NHS England and Association of the British Pharmaceutical Industry work programme on medicines optimisation is ongoing, which seeks to improve outcomes and value from all medicines;

    – NHS England works closely with Academic Health Science Networks to accelerate the adoption and diffusion of innovation.

    The Department’s analysis of medicines spend for the first year of the PPRS shows that branded medicines spend grew by 8.2%, with new medicines on the Innovation Scorecard seeing growth of 18.4%. Further details have been published on the Government’s website at:

    https://www.gov.uk/government/publications/analysis-of-growth-in-branded-medicines-2013-to-2014

    Commissioners are legally required to fund drugs and treatments recommended in NICE technology appraisal and highly specialised technology guidance within three months of NICE’s guidance being published. There is provision for this funding period to be extended where there are particular barriers to implementation within three months.

  • Robert Neill – 2022 Speech on the Northern Ireland Protocol Bill

    Robert Neill – 2022 Speech on the Northern Ireland Protocol Bill

    The speech made by Robert Neill, the Conservative MP for Bromley and Chislehurst, in the House of Commons on 27 June 2022.

    This is a profoundly serious debate, because it is a profoundly serious thing for any country to depart from its international obligations. It is not an impossible thing to do, but it is a profoundly serious thing to do, and it should be done only under circumstances of the most exceptional nature and on the most profound and compelling evidence. That, again, is possible, but we need to test whether we are yet there.

    Against that background, I start by saying that everybody accepts the importance of the Northern Ireland protocol as an attempt to reconcile conflicts that were inevitable post Brexit, given the nature of the Brexit that was decided upon. Equally, we must be honest and say that, despite best endeavours, it has failed to reconcile those problems. Therefore, I accept as much as anyone that it does need to change, and change significantly.

    I recognise that there are economic dislocations, not in all of the Northern Ireland economy, but enough for it to be a serious problem, and certainly the non-functioning of the Executive at the very least gives rise to the risk of real societal divisions and tensions. Those are circumstances where it is envisaged that there might be changes, but we have to think about whether we are acting proportionately and wisely in what we do.

    Looking at the position legally, it is this: logically, there is already a route set out in the protocol by which these matters can be addressed. If there is to be change, there is of course provision in article 13.8 and subsequent articles, and I think article 164 of the withdrawal agreement, for changes to deal with “deficiencies, or…situations unforeseen.” One might well argue that some of the ways the protocol has been interpreted—largely, I would accept, because of the intransigence frequently adopted by the EU side and the unwillingness to extend Mr Šefčovič’s mandate—have contributed to that. That might make a case for acting under those articles.

    I also accept that the protocol was never expected to be permanent; it was always envisaged that it could be changed. Equally, however, all that presupposed that it would be changed by negotiation, rather than unilateral action. That is the difficulty we must face here. How do we reconcile the primacy of the Good Friday agreement, which I accept both politically and legally, and the need for adjustment with maintaining our reputation as a country that sticks by its word? Pacta sunt servanda, as we all say.

    How do we get around that? The Bill, as currently drafted, does not achieve that. It could do, were it to be amended, and that is why I do not take the view that we should exclude the idea of legislation to act in the way envisaged, but it needs some serious thought. At the moment, as I have suggested elsewhere, it raises as many questions as it answers—and we do not have the answers.

    If we are not to go down the route of renegotiated changes envisaged in the protocol, and there may be pressing reasons why that is not achievable in the timeframe available, we then have the ability under article 16 to take emergency safeguarding measures. Those have not yet been used. I agree with my right hon. Friend the Member for Chingford and Woodford Green (Sir Iain Duncan Smith) that that might be an appropriate route to use. It might not solve all the problems, but, for reasons I will come to, I would suggest that legally it would put the UK in a better position were it then to seek to go further.

    If we are to rely upon necessity, as the Government do—I concede that it is a respectable and established concept in international law, but also one that, it is well known, must be used exceptionally and therefore rarely and with a high evidence threshold to be met—it would be much better to have exhausted all opportunities. Indeed, that is part of the doctrine. To invoke necessity, there must be a grave and imminent threat. I agree with my right hon. and learned Friend the Member for South Swindon (Sir Robert Buckland) that it need not be immediate, but it must be something more than merely contingent or a possibility, and it must be evidenced.

    It seems to me that we do not yet have the evidence before us. Before this Bill passes its stages in this House, the Government, who are working on their evidence base and say they will be able to draw together the facts that can be applied to the evidence to substantiate the grounds of necessity, ought to come to the House with that evidence. Going forward, rather than having exceedingly wide Henry VIII powers, I would think it much preferable that we do as we did with the UK Internal Market Bill and require the Government, when they wish to disapply an element of the protocol, to come to the House and seek its endorsement, having presented that evidence to it.

    Similarly, I do not see why clause 18, with such wide powers to do virtually anything, is acceptable—that should come back to the House—or why it is necessary in clause 20 to seek to oust the jurisdiction of the European Court at this stage. As yet, the potential jurisdiction of the ECJ is at least contingent and potential, and therefore not pressing and immediate in relation to the doctrine of necessity.

    I will not support the Bill tonight, but I will not vote against it; I am deliberately abstaining tonight to see how the Bill develops. It could be amended into a workable form, but it comes with very many caveats and a lot of questions that Ministers need to answer. I hope they will seek to address those.